As Sun Sets On Copaxone, Teva Looks To New BD Horizons
This article was originally published in The Pink Sheet Daily
Executive Summary
Acting CEO Eyal Desheh said the company will be more open-minded about business development during the company’s fourth quarter financial call Feb. 6. Investors will have to wait to hear from incoming CEO Erez Vigodman for any new strategy to be articulated, however.